Results 131 to 138 of about 2,046 (138)
[Descriptive study of events allegedly attributable to mpox vaccination in Brazil in 2023]. [PDF]
Cad Saude PublicaSilva RMA, Kobayashi CD, Martins AF, Araújo ACM, Andrade PHS, Nóbrega MEBD, Cabral CM, Moraes MB, Cardoso FD, Victer TNDF, Krummenauer A, Soares ROPS, Fernandes EG, Percio J. +13 moreeuropepmc +1 more sourceSafety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals. [PDF]
Rev Inst Med Trop Sao PauloMiyaji KT, Ibrahim KY, Infante V, Moreira RM, Santos CFD, Belizário JC, Pinto MIM, Marinho AKBB, Pereira JM, Mello LS, Silva VGLD, Sato PK, Strabelli TMV, Ragiotto L, Pacheco PHTM, Braga PE, Loch AP, Precioso AR, Sartori AMC, Study Group, França JÍ, Lima MA, Ando MCS, Rodrigues CCM, Song ATW, Lara AN, Belizário AC, Lima AHSB, Zanetti ACB, Paulo ARDSA, Rosa BMDS, Moraes BDGC, Oliveira BR, Picone CM, Aranda CS, Troli CP, Kokron CM, Terrabuio DRB, Abdala E, David Neto E, Nakanishi ÉYS, Lima FMS, Firmino FB, Santos FBAD, Bacal F, Fatobene G, Santana JO, Kalil J, Barbosa J, Gonçalves LP, Otuyama LJ, Pierrotti LC, Compte LCM, Marinho L, Chaer LN, Seguro LF, Azevedo LS, Ueda MA, Terreri MT, Barros MAMT, Grecco O, Sejas ONE, Musqueira PT, Ito RKL, Teixeira SSS, Fidalgo S, Costa SF, Campos SV, Fernandes TH, Rocha VG, Coelho VC. +70 moreeuropepmc +1 more sourceAge and Clinical Outcomes of Immune Checkpoint Inhibitor Toxicities in Portugal: A Decade of Pharmacovigilance. [PDF]
Cancers (Basel)Pina-Cabral T, Pereira J, Paulo-Fernandes J, Silva M, Fontes-Sousa M, Anacleto M, Lobo-Martins S, Mirco A, Miranda H, Martins A, Cavaco P. +10 moreeuropepmc +1 more source